Johnson & Johnson (NYSE: JNJ) was downgraded by equities research analysts at First Global from an “outperform” rating to a “market perform” rating in a research note issued to investors on Thursday.
Separately, analysts at Goldman Sachs (NYSE: GS) cut their EPS estimates on shares of Johnson & Johnson in a research note on Wednesday. They now have a “neutral” rating and a $70.00 price target on the stock. Analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research note to investors on Wednesday, January 25th. They now have a $68.00 price target on the stock. Also, analysts at Piper Jaffray (NYSE: PJC) cut their price target on shares of Johnson & Johnson to $68.00 in a research note to investors on Wednesday, January 25th.
Johnson & Johnson is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the health care field. It has more than 250 operating companies conducting business worldwide. The Company’s operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Company and its subsidiaries operate 139 manufacturing facilities occupying approximately 21.8 million square feet of floor space. Within the United States, 7 facilities are used by the Consumer segment, 11 by the Pharmaceutical segment and 36 by the Medical Devices and Diagnostics segment. In December 2011, Symmetry Medical Inc. acquired the surgical instruments business of Codman & Shurtleff, Inc., a Johnson & Johnson company.
Shares of Johnson & Johnson traded up 0.11% during mid-day trading on Thursday, hitting $65.76. Johnson & Johnson has a one year low of $57.50 and a one year high of $68.05. The stock’s 50-day moving average is $65.16 and its 200-day moving average is $64.27. The company has a market cap of $179.7 billion and a P/E ratio of 18.82.
Stay on top of analysts' coverage with our daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day. Click here to register.